LACTOLOGY FOUNDATION

Toxico-Lactological Monograph: ATC Class A08 – Antiobesity Preparations, Excluding Diet Products

ATC class and general pharmacology

The Anatomical Therapeutic Chemical (ATC) classification system code A08 designates "Antiobesity preparations, excluding diet products," representing a major therapeutic subgroup of anatomical main group A (Alimentary Tract and Metabolism). Pharmacotherapy within ATC class A08 is primarily indicated for chronic weight management in adult patients presenting with obesity (body mass index [BMI] $\ge 30\text{ kg/m}^2$) or overweight (BMI $\ge 27\text{ kg/m}^2$) in the presence of at least one weight-related cardiometabolic comorbidity, such as hypertension, dyslipidemia, or type 2 diabetes mellitus. The broader class comprises structurally and functionally heterogeneous compounds that alter energy homeostasis through distinct central, peripheral, or systemic metabolic pathways.

The World Health Organization (WHO) structures ATC class A08 into three major pharmacological subcategories:

• A08AA: Centrally acting antiobesity products – This subclass includes sympathomimetic amines, monoamine reuptake inhibitors, selective serotonin receptor agonists, melanocortin receptor agonists, and fixed-dose neuro-behavioral combinations. Representative agents include phentermine (A08AA01), fenfluramine (A08AA02), amfepramone (A08AA03), dexfenfluramine (A08AA04), mazindol (A08AA05), sibutramine (A08AA10), lorcaserin (A08AA11), setmelanotide (A08AA12), as well as combination formulations such as phentermine/topiramate (A08AA51) and bupropion/naltrexone (A08AA62). The primary mechanism of action for centrally acting agents involves modulating neurotransmission within the arcuate nucleus of the hypothalamus and mesolimbic reward pathways. Sympathomimetic agents enhance norepinephrine and dopamine release or block their reuptake, thereby activating pro-opiomelanocortin (POMC) neurons to induce appetite suppression and early satiety. Serotonergic agents modulate central appetite signals via specific $5\text{-HT}_{2\text{C}}$ receptor agonism, while setmelanotide selectively activates melanocortin-4 (MC4R) receptors to restore impaired energy balance pathways in specific genetic obesity syndromes.
• A08AB: Peripherally acting antiobesity products – This subclass is predominantly represented by gastrointestinal lipase inhibitors, most notably orlistat (A08AB01). Orlistat exerts its therapeutic effect locally within the lumen of the stomach and small intestine by forming a covalent bond with the active serine residue of gastric and pancreatic lipases. Inactivation of these enzymes prevents the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides, resulting in a dose-dependent reduction of systemic fat absorption by approximately 30%.
• A08AX: Other antiobesity drugs and emerging metabolic mimetics – This group historically contained central cannabinoid receptor-1 (CB1) antagonists such as rimonabant (A08AX01). In modern clinical pharmacology, this therapeutic space intersects with long-acting peptide-based incretin mimetics, including glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide, semaglutide) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (e.g., tirzepatide). These peptide therapeutics engage central GLP-1 receptors in the hypothalamus and hindbrain to promote satiety, while peripherally delaying gastric emptying and optimizing glucose-dependent insulin secretion.

Toxicological Profile

The toxicological profiles across ATC class A08 reflect the distinct target organs, absorption kinetics, and off-target receptor profiles of its constituent subclasses. Systemic toxicities are predominantly observed with small-molecule centrally acting agents, whereas peripherally acting inhibitors display localized gastrointestinal toxicities, and macromolecular peptides exhibit specific pancreatobiliary and gastrointestinal adverse profiles.

Centrally acting sympathomimetics and monoaminergic agents (A08AA) possess a toxicological footprint driven by systemic adrenergic and serotonergic hyperstimulation. Acute toxicity or excessive dose accumulation of sympathomimetic amines manifests as severe cardiovascular dysfunction, including resting tachycardia, malignant hypertension, cardiac dysrhythmias, and acute coronary vasospasm. Central nervous system toxicities include profound agitation, insomnia, psychosis, hyperthermia, and a lowered seizure threshold. Chronic administration of historic serotonergic agents, such as fenfluramine and dexfenfluramine, demonstrated severe cardiotoxicity characterized by cardiac valvulopathy and primary pulmonary arterial hypertension. These adverse events were subsequently mapped to off-target agonism at $5\text{-HT}_{2\text{B}}$ receptors expressed on cardiac valve interstitial cells and pulmonary artery smooth muscle cells, inducing fibroblast proliferation and structural vascular remodeling that ultimately prompted global regulatory withdrawals. Similarly, sibutramine was withdrawn following clinical trials demonstrating an elevated incidence of non-fatal myocardial infarction and stroke. Dual-agent neuro-behavioral formulations like bupropion/naltrexone carry specific toxicological risks, including neuropsychiatric disturbances, severe depressive exacerbations, suicidal ideation, and elevated cardiovascular stress parameters.

Peripherally acting lipase inhibitors (A08AB), exemplified by orlistat, display minimal systemic toxicity due to poor gastrointestinal absorption ($F < 1\%$). The primary adverse profile is localized within the gastrointestinal tract, causing steatorrhea, oily spotting, fecal urgency, flatulence with discharge, and abdominal cramps. However, chronic luminal fat malabsorption gives rise to significant secondary metabolic toxicities. The presence of unabsorbed free fatty acids in the intestinal lumen leads to preferential binding of calcium to dietary fats, preventing the normal precipitation of insoluble calcium oxalate. Unbound luminal oxalate is subsequently hyper-absorbed across the colonic mucosa, resulting in enteric hyperoxaluria. This secondary metabolic disruption creates a pronounced risk of calcium oxalate nephrolithiasis, nephrocalcinosis, and oxalosis-induced acute renal failure. Furthermore, chronic lipase inhibition impairs the solubilization and absorption of fat-soluble vitamins (A, D, E, and K), which can lead to clinical deficits, such as hypoprothrombinemia secondary to Vitamin K depletion.

Peptide-based incretin mimetics and multi-receptor agonists (A08AX / Incretin class) exhibit a toxicological profile dominated by gastrointestinal motor disruption. Dose-dependent adverse events include persistent nausea, emesis, severe diarrhea, and gastroparesis stemming from potent delayed gastric emptying. Severe systemic toxicities include acute pancreatitis, necrotizing pancreatitis, and biliary tract disorders (cholelithiasis and acute cholecystitis), which are driven by rapid weight loss dynamics and altered gallbladder contractility. Preclinical carcinogenicity evaluations of GLP-1 receptor agonists demonstrated dose-dependent thyroid C-cell hyperplasia and medullary thyroid carcinomas in rodent models via receptor-mediated pathways, establishing strict clinical warnings regarding personal or familial histories of thyroid neoplasia.

Lactation Pharmacology and Infant Exposure

The transfer of pharmacological agents from maternal plasma into human milk occurs primarily via passive diffusion across the lactating mammary epithelium. The rate and extent of drug excretion into human milk are governed by physicochemical properties: maternal serum concentration, molecular mass ($MW$), plasma protein binding ($f_u$), lipophilicity, and the drug's ionization constant ($pKa$) relative to the physiological $pH$ differential between maternal plasma ($\approx 7.4$) and human milk ($\approx 7.0 - 7.2$).

Small-molecule centrally acting agents (A08AA) possess physicochemical profiles that strongly favor transit across the blood-milk barrier. Compounds within this subclass generally exhibit low molecular mass ($MW < 400\text{ Da}$), lipophilic structures, basic $pKa$ values, and low-to-moderate plasma protein binding. Basic molecules experience significant ion trapping within the slightly acidic environment of human milk, as the ionized drug fraction becomes structurally hindered from diffusing back into maternal circulation. Consequently, centrally acting sympathomimetics can achieve elevated Milk-to-Plasma ($M/P$) ratios and Relative Infant Doses ($RID$) that may exceed the standard $10\%$ safety threshold. Infant systemic exposure to these excreted compounds carries substantial risks of adrenergic overstimulation, including severe irritability, sleep disturbances, tachypnea, tachycardia, hypertension, and poor feeding. Furthermore, central dopaminergic activity of certain sympathomimetics can suppress maternal anterior pituitary prolactin secretion, leading to an unwanted reduction in overall milk supply.

Peripherally acting lipase inhibitors (A08AB) demonstrate unique lactation pharmacokinetics due to their lack of systemic bioavailability. Following oral ingestion of orlistat, maternal plasma concentrations remain below quantifiable limits ($< 5\text{ ng/mL}$). In the absence of an appreciable maternal serum concentration gradient, passive diffusion across the mammary alveolar epithelium cannot take place. The excretion of orlistat into human milk is therefore zero ($RID \approx 0\%$), resulting in no direct systemic exposure or toxicological risk to the breastfed infant. Nevertheless, indirect lactological risks must be evaluated: unsupplemented maternal fat-soluble vitamin malabsorption can reduce the maternal plasma pool of micronutrients, leading to a secondary decline in fat-soluble vitamin concentrations (particularly Vitamins A and E) within human milk, which may compromise infant nutritional status.

Macromolecular peptide therapeutics (A08AX / Incretin class) present a favorable excretion profile governed by molecular size and metabolic degradation. Modern incretin peptides, such as liraglutide ($MW \approx 3751\text{ Da}$), semaglutide ($MW \approx 4113\text{ Da}$), and tirzepatide ($MW \approx 4814\text{ Da}$), feature high molecular weights that exceed the passive diffusion threshold of tight alveolar junctions in mature lactation ($MW > 800 - 1000\text{ Da}$). Additionally, these molecules exhibit extensive binding to maternal plasma albumin ($> 99\%$), leaving a negligible free drug fraction available for diffusion. Clinical lactation studies examining subcutaneous semaglutide demonstrated that drug levels in human milk remained below detectable analytical limits ($< 1.7\text{ }\mu\text{g/L}$), yielding an estimated mean $RID \le 1.12\%$. Furthermore, if trace peptide amounts were ingested via milk, the oral bioavailability of peptide structures in the infant gastrointestinal tract is practically zero ($< 0.1\%$). Ingested peptides undergo rapid proteolytic cleavage by pepsin and luminal pancreatic endopeptidases in the infant digestive tract, hydrolyzing the active molecule into inactive amino acids prior to systemic absorption. A critical exception involves oral formulations of incretin peptides that incorporate synthetic absorption enhancers, such as salcaprozate sodium (SNAC). SNAC facilitates transcellular gastric absorption by modifying local $pH$ and membrane fluidity. Unlike the peptide, SNAC is systemically absorbed and can transfer into human milk, presenting uncharacterized metabolic risks to the neonate.

Lactational stage and infant gut maturity significantly modulate theoretical exposure risks. During early lactogenesis (colostrum phase, days 1–3 post-partum), wide paracellular gaps between alveolar epithelial cells permit greater transient passage of larger proteins and maternal serum constituents into milk. Additionally, premature neonates exhibit increased intestinal mucosal permeability and reduced luminal proteolytic activity, which could theoretically allow small amounts of intact ingested peptides to cross into infant plasma. Finally, rapid maternal adipose tissue breakdown induced by potent antiobesity agents can mobilize lipophilic environmental toxicants stored in maternal fat stores (e.g., organochlorines) into maternal circulation and milk, while severe caloric restriction can alter overall milk fat content and lipid composition.

Lactological safety assessment and clinical recommendations

The lactological safety assessment of ATC class A08 antiobesity medications requires balancing maternal cardiometabolic health priorities against potential infant toxicities and the preservation of successful lactation. Clinical recommendations vary significantly by subclass, reflecting differences in systemic absorption, milk transfer dynamics, and infant oral bioavailability.

Centrally acting sympathomimetics and monoamine modulators (A08AA) are generally considered incompatible with breastfeeding. The combination of elevated milk transfer ($RID > 10\%$), risk of adrenergic toxicity in the infant (irritability, tachycardia, hypertension), and potential suppression of maternal prolactin secretion dictates that these agents should be avoided during active lactation. If maternal therapy with central sympathomimetics is clinically mandatory, breastfeeding should be paused, or alternative therapeutic classes should be selected.

Peripherally acting lipase inhibitors (A08AB), specifically orlistat, represent a compatible pharmacotherapeutic choice during lactation. Because systemic absorption is minimal and milk excretion is absent, orlistat poses no direct pharmacological risk to the nursing infant. Prescribing physicians must mandate daily maternal supplementation with a comprehensive multivitamin containing fat-soluble vitamins (A, D, E, K) to prevent maternal depletion and maintain optimal micronutrient levels in human milk. To ensure uninhibited micronutrient absorption, the multivitamin should be taken at least two hours before or after orlistat administration.

Subcutaneous peptide-based incretin mimetics (A08AX / Incretin class) demonstrate a favorable lactological safety profile and may be considered with appropriate clinical oversight when maternal therapy is indicated. Their high molecular mass, extensive protein binding, low excretion rates into milk ($RID < 1.5\%$), and gastrointestinal degradation in the infant establish a low probability of systemic infant exposure. Subcutaneous formulations of liraglutide, semaglutide, or tirzepatide are preferred over oral formulations containing salcaprozate sodium (SNAC), which should be avoided due to unknown excipient exposure risks. Caution should be exercised when initiating treatment during the early neonatal period (first 14 days post-partum) or in premature infants due to heightened gut permeability.

Clinicians managing weight disorders in breastfeeding mothers should follow a structured clinical protocol:

• First, non-pharmacological interventions—including nutritional modifications, structured exercise, and behavioral therapy—should form the foundation of postpartum weight management. Pharmacotherapy should be reserved for individuals with clear cardiometabolic indications.
• Second, when selecting pharmacotherapy, prescribers should prioritize peripherally acting lipase inhibitors or subcutaneous incretin mimetics over centrally acting sympathomimetics.
• Third, monitoring routines must be established for the infant dyad. Infant growth trajectories should be tracked using standardized WHO growth charts. Infants exposed to maternal incretin therapy should be observed for gastrointestinal changes (e.g., loose stools, vomiting) or altered feeding patterns.